<- Go Home
Nyxoah SA
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Market Cap
EUR 181.6M
Volume
37.2K
Cash and Equivalents
EUR 22.7M
EBITDA
-EUR 72.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 3.2M
Profit Margin
65.27%
52 Week High
EUR 11.15
52 Week Low
EUR 3.84
Dividend
N/A
Price / Book Value
2.47
Price / Earnings
-2.30
Price / Tangible Book Value
2.49
Enterprise Value
EUR 161.0M
Enterprise Value / EBITDA
-2.25
Operating Income
-EUR 73.8M
Return on Equity
79.77%
Return on Assets
-34.84
Cash and Short Term Investments
EUR 43.0M
Debt
EUR 22.4M
Equity
EUR 73.4M
Revenue
EUR 4.9M
Unlevered FCF
-EUR 38.0M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium